MH370 co-pilot made mid-flight phone call: Report

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Paris, Apr 17: The number of coronavirus-related deaths in France has increased by 753 to 17,920 over the past 24 hours, with the total case count now standing at 108,847, Jerome Salomon, the head of the state health agency, said on Thursday.

On Wednesday, the country reported a total of 106,206 cases, including a record 1,438 new fatalities. Salomon specified that it was not the daily death toll, as the data had been compiled over the last three-day weekend.

"The total number of victims since March 1 is 17,920," Salomon said at a briefing on Thursday.
He noted that 11,060 of them had died in hospitals, and 6,860 others in social and medical-social facilities.

President Emmanuel Macron on Monday extended nationwide movement restrictions, which had been introduced due to the epidemic, until May 11. Afterwards, the country is set to gradually reopen kindergartens, schools and universities.

Wuhan, Jun 9: China on Tuesday dismissed as "incredibly ridiculous" a Harvard study, which pointed to a surge in traffic outside Wuhan hospitals from August 2019 suggesting that the coronavirus hit the area far earlier than reported.

A whitepaper on coronavirus released by China on Sunday said the virus was first noticed on December 17 and Chinese virologists confirmed human-to-human transmission on January 19, prompting authorities to impose lockdown of Wuhan from January 23.

US President Donald Trump and leaders of several countries have accused China of not being transparent in reporting the deadly disease, leading to huge human casualties and economic crisis across the world.

The new study by Harvard researchers says satellite images show an increase in traffic outside five hospitals in Wuhan from late August to December.

The traffic spike coincided with a rise in online searches for information on symptoms like "cough" and "diarrhoea".

China said the study was "ridiculous" and based on "superficial" information, BBC reported.

It is believed that the virus first appeared in China some time in November. Authorities reported a cluster of pneumonia cases with an unknown cause to the World Health Organization (WHO) on December 31.

"Clearly, there was some level of social disruption taking place well before what was previously identified as the start of the novel coronavirus pandemic," Dr John Brownstein, who led the research, told ABC news.

The study has not been peer-reviewed.

The researchers examined commercial satellite data from outside five Wuhan hospitals, comparing data from late summer and autumn 2018 to the same time period in 2019.

In one case, researchers counted 171 cars parked at one of Wuhan''s largest hospitals, Tianyou Hospital, in October 2018.

Satellite data from the same time in 2019 showed 285 vehicles in the same place, an increase of 67 per cent.

A surge in online searches for words associated with the symptoms of coronavirus on the Chinese search engine Baidu seemed to emerge at the same time.

"This is all about a growing body of information pointing to something taking place in Wuhan at the time," Dr Brownstein said.

"Many studies are still needed to fully uncover what took place and for people to really learn about how these disease outbreaks unfold and emerge in populations. So this is just another point of evidence," he said.

Asked for her reaction at the media briefing, Chinese Foreign Ministry spokeswoman Hua Chunying dismissed the findings as "incredibly ridiculous".

"I think it is ridiculous, incredibly ridiculous, to come up with this conclusion based on superficial observations such as traffic volume," she said.

"(I have) Not seen the research you mentioned. If the conclusion is drawn based on traffic volumes (and) other superficial observations, it won’t be a sound conclusion," she said and referred to the allegations about the COVID-19 originating from the Wuhan Institute of Virology (WIV) by Trump.

"That allegation was proved to be wrong," she said.

When pointed out that China says it respects science based inquiry and Harvard is one of the top universities in the world, Hua said, "on the origin of virus there are lot of conspiracy theories against China”.

"That is very unfair. At the moment, the pressing task is to enhance coordination to contain the spread of the virus. Someday, I am sure the truth will be out. China deserves a fair and objective evaluation," she said and referred to the whitepaper released by the Chinese government detailing evolution of coronavirus in Wuhan and how Beijing handled the situation.

Recently, the World Health Assembly (WHA), the decision-making body of Geneva-based World Health Organization (WHO), passed a resolution to probe the origin of the virus. China also backed the resolution.

As of Monday, the overall confirmed cases on the mainland had reached 83,043, including 58 patients who were still being treated, with no one in severe condition, China’s National Health Commission, (NHC) said.

Altogether 78,351 people had been discharged after recovery and 4,634 people had died of the disease, it said.